Evidence map›Paper›PMID 41702207›Full record

ArticleJACC. Advances2026

Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant Hypertension: MOMENTUM Rationale and Design.

Jorge Plutzky, Pam R Taub, Deepak L Bhatt, Omar Al Dhaybi, Vanita R Aroda, Jan N Basile, Michael J Bloch, Matthew Budoff, Robert S Busch, John B Buse and 12 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06829537 (Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension in the United States of America), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06829537 completednot on this map

Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension in the United States of America (MOMENTUM)

TypeobservationalSponsorCorcept TherapeuticsRan2025 to 2026Enrolled1,143ConditionsResistant Hypertension, Hypercortisolism
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jorge PlutzkyBrigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: jplutzky@bwh.harvard.edu.
Pam R TaubUniversity of California-San Diego School of Medicine, La Jolla, California, USA.
Deepak L BhattMount Sinai Fuster Heart Hospital and Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Omar Al DhaybiMount Sinai Fuster Heart Hospital and Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Vanita R ArodaBrigham and Women's Hospital, Boston, Massachusetts, USA.
Jan N BasileMedical University of South Carolina, Charleston, South Carolina, USA.
Michael J BlochRenown Institute for Heart and Vascular Health and University of Nevada Reno School of Medicine, Reno, Nevada, USA.
Matthew BudoffLundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, West Carson, California, USA.
Robert S BuschAlbany Medical College, Albany, New York, USA.
John B BuseUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Dianne CheungUniversity of California Los Angeles, Los Angeles, California, USA.
Elena A ChristofidesEndocrinology Associates, Columbus, Ohio, USA.
Ralph A DeFronzoUniversity of Texas Health Science Center, San Antonio, Texas, USA.
Rodolfo J GalindoUniversity of Miami Miller School of Medicine, Miami, Florida, USA.
Yehuda HandelsmanThe Metabolic Institute of America, Tarzana, California, USA.
Luke LaffinCleveland Clinic, Cleveland, Ohio, USA.
John C ParkerAccellacare Research/Wilmington Health, Wilmington, North Carolina, USA.
Florian RaderCedars-Sinai Medical Center, Los Angeles, California, USA.
Julio RosenstockVelocity Clinical Research at Medical City Dallas, Dallas, Texas, USA.
Lance A SloanTexas Institute for Kidney and Endocrine Disorders, Lufkin, Texas, USA.
Iulia Cristina TudorCorcept Therapeutics Incorporated, Redwood City, California, USA.
Daniel EinhornCorcept Therapeutics Incorporated, Redwood City, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypertension is a leading modifiable risk factor for cardiovascular disease and premature death among adults. Up to 18% of individuals with hypertension have resistant hypertension (rHTN), which substantially increases the risk of adverse clinical outcomes. Endogenous hypercortisolism can result in rHTN through multiple mechanisms.

objectivesMOMENTUM (NCT06829537) is the first large, observational, multicenter study examining the prevalence of endogenous hypercortisolism among adults with rHTN in the United States.

methodsTarget enrollment is approximately 1,000 participants. To be eligible, adults aged ≥18 years must have rHTN, defined using the American Heart Association criteria (systolic blood pressure ≥130 mm Hg despite ≥3 antihypertensive medications of different classes at maximally tolerated doses, including a diuretic, or ≥4 medications from different classes regardless of systolic blood pressure). Endogenous hypercortisolism is defined as cortisol level >1.8 μg/dL on the 1-mg overnight dexamethasone suppression test with adequate dexamethasone (≥140 ng/dL). The primary endpoint is endogenous hypercortisolism prevalence.

conclusionsMOMENTUM will provide new insight into endogenous hypercortisolism in patients with resistant hypertension.

Indexed as

cortisoldexamethasone suppression testendogenous hypercortisolismprevalenceresistant hypertension

Identifiers

PMID41702207
PMCPMC12930052

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.